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Abstract
Background: This study compares annual ambulatory care expenditures per patient with type 2 diabetes mellitus
(T2DM) in France according to treatment phase and renal function status.
Methods: Records from patients with T2DM were extracted from a health insurance database. Patients were
classified in subgroups, by treatment phase: oral/GLP1 monotherapy, double therapy, triple therapy or insulin
therapy, and according to renal function status (identified using pharmacy, lab and consultation claims). Annual
ambulatory expenditures were estimated from the national insurance perspective by year (from 2005 to 2010) and
subgroup.
Results: The number of patients ranged from 9,682 to 11,772 between 2005 and 2010. The average annual
expenditure per individual in 2010 ranged from €3,017 (standard deviation: €3,829) for monotherapy to €3,609 ±
€3,801 for triple therapy, and €7,398 ± €5,487 with insulin (adjusted ratio insulin therapy/monotherapy: 2.36,
p < 0.001). Similar differences between treatement stages were found in previous years. Additional costs for insulin
were mainly related to nursing care (multiplied by 18.42, p < 0.001), medical devices and pharmacy costs. DM-
attributable drug costs were mainly related to antidiabetic drugs (28% for monotherapy to 71% for triple therapy),
but also to cardiovascular system drugs (21% for monotherapy to 51% with insulin) and nervous system drugs
(up to 8% with insulin). Declining renal function was associated with an increase in expenses by 12% to 53%
according to treatment stage.
Conclusions: Overall, ambulatory care expenditures increase with treatment escalation and declining renal function
amongst patients with T2DM. Insulin therapy is associated with substantially increased costs, related to pharmacy,
nursing care and medical device costs.
Keywords: Cost analysis, Type 2 diabetes mellitus, Oral antidiabetics, Insulin, Renal function
Background
With the increasing prevalence of treated type 2 diabetes
mellitus (T2DM) in France, from 2.6% to 4.4% among
people covered by the national health insurance scheme
between 2000 and 2009 [1], costs related to diabetes in-
creased from 7.1 billion € in 2001 to 12.5 billion in 2007
[2]. These expenditures represented approximately 8.5%
of the National Objective of Healthcare Expenditure
(144.8 billion € in 2007).
As an ever-increasing portion of gross domestic product
is spent on health care, economic considerations are given
increasing importance in the development of treatment
guidelines and drug reimbursement decisions. This is il-
lustrated in France by the recent introduction of health
economic guidelines by the Haute Autorité de Santé
(HAS). The HAS published recommendations for the
management of T2DM in France in 2006 [3]. Therapeutic
escalation was recommended to maintain glycemic con-
trol with an HbA1c < 48 mmol/mol (6.5%) from mono-
therapy with an oral antidiabetic (Metformine), to oral
double therapy, then to triple therapy or insulin therapy.
Since the publication of these recommendations, incretin
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mimetics, i.e. Dipeptidyl peptidase-4 (DPP4) inhibitors
and Glucagon-like peptide-1 (GLP-1), have been intro-
duced on the market.
Latest data on the cost of diabetes in France come
from the 2007 ENTRED study (Echantillon national
témoin représentatif des personnes diabétiques) [4],
which described healthcare expenditures in a nationally
representative sample of people covered by the largest
national health insurance fund, living in metropolitan
France. According to this study, average annual individ-
ual expenditures for treating people with diabetes were
€5,341 in 2007. The first category of expenditure was
hospitalisation (over 38%). The second category was
drug costs, estimated at €1,343 to €1,402 (25-26%)
according to data sources, or €3.67/day to €3.84/day.
Antidiabetics represented 23% of the drug costs (oral
medications: 13% and insulin: 10%). The main other
drug categories were cardiovascular treatments (37% of
drug reimbursements), lipid-lowering drugs (9%) and
anti thrombotic drugs (6%).
Among T2DM complications, chronic renal disease
(CRD) limits the therapeutic options because a reduced
glomerular filtration rate results in the accumulation of
certain drugs and/or their metabolites. Health care costs
among persons with T2DM with end-stage renal failure
were estimated to be 3 to 4 times higher compared to
T2DM cases without related complications [5].
Several important changes occurred since the
ENTRED study. First, new therapeutic classes have been
introduced, as previously mentioned. This could have
important economic consequences as prices of these
new drugs are substantially higher than those of older
andiabetics. Secondly, diabetes treatments were intensi-
fied in the last decade. According to ENTRED, mono-
therapy was less frequent in 2007 compared to 2001
(36% vs 41%) while combination of oral antidiabetics
(OAD) and combination therapy with insulin were more
frequent (34% vs 32% and 21% vs 19%). This trend was
pursued in recent years, with use of basal insulins grow-
ing at a faster rate than oral antidiabetics [6]. On the
other hand, a limitation of the ENTRED study is that it
did not provide costs estimations according to treatment
escalation.
The objectives of this new study were (1) to update
and enhance 2007 ENTRED study figures with data
obtained in recent years up to 2010 including the period
of launch of new antidiabetic oral treatment (DPP4 in-
hibitors and GLP1 analogs); (2) to estimate the diabetes-
attributable annual expenditures based on a comparison
vs. matched individuals without diabetes; (3) to compare
annual expenditures per patient between treatment
stages and according to renal function status (RFS) and
to identify the main cost components driving differences
between stages and according to RFS.
Methods
Study design and data source
We performed a retrospective cross-sectional analysis
using data from the ‘Echantillon Generaliste de
Beneficiaires’ (EGB) database. The EGB database con-
tains records of reimbursements made by the national
health insurance for ambulatory care, for a sample of
530,000 subjects, representative of the general popula-
tion affiliated with the French health insurance system.
The sample is obtained by 1/97th random sampling with
control for distribution of age and gender. This
anonymized database includes patient demographics,
health plan enrolment information, and reimbursed
amounts for outpatient procedures, laboratory tests,
physician visits and outpatient drug dispensing claims,
along with specialty of the prescriber. It contains neither
direct clinical information nor results of the lab tests.
EGB is a completely anonymized database with no
possible interaction with the persons contributing infor-
mation. The identification of persons included in the
EGB sample is protected by an anonymization process
with two cryptographic levels, a procedure conforming
to French data protection legislation. The use of EGB for
medical research has been approved by the National
Commission for Informatics and Liberties (CNIL). The
conditions of use of EGB for research purposes and the
authorized accesses are stated by law. Researchers in-
volved in this study were authorized to use the database,
and have been trained in its use. The study were
declared to and approved by the National Institute of
Medical Research and Statistics (INSERM).
Observation period
Patients were monitored between 2005 and 2010 from
the date of the first prescription of antidiabetic drug
(oral and/or insulin), or from the date of notification of
chronic disease/ALD status for T2DM. DM is one of a
list of long-term conditions, designated as “Affections
Longue Durée” for which patients are entitled to 100%
reimbursement of health care. The observation period
was partitioned in calendar years. Annual healthcare ex-
penditures in different years were compared between
phases of treatment (from 2005 to 2010).
Patient selection and classification
Patients were included in the treated T2DM cohort if
the antidiabetics (ADs) or insulin were dispensed for
more than 80% of days over 15-months during the
follow-up period. Patients with any evidence of preg-
nancy, gestational diabetes or any other type of diabetes
during the treatment period were excluded.
In absence of complete diagnostic information in the
database, patients with declining renal function (DRF)
were identified as patients with at least one of the
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Figure 1 Selection of patient with T2DM.
Table 1 Number of patients analyzed
Year 2005 2006 2007 2008 2009 2010
Diabetics patients followed up (1) 19,005 20,434 21,512 22,566 23,713 24,862
Patients analyzed 9,682 10,397 11,094 11,772 11,583 9,734
Monotherapy 5,792 59.8% 5,890 56.7% 6,080 54.8% 6,390 54.3% 6,065 52.4% 4,764
Double therapy 2,484 25.7% 2,815 27.1% 3,029 27.3% 3,147 26.7% 3,100 26.8% 2,770 28.5%
Triple therapy 355 3.7% 447 4.3% 551 5.0% 657 5.6% 730 6.3% 803 8.2%
Polytherapy 14 0.1% 28 0.3% 44 0.4% 66 0.6% 73 0.6% 98 1.0%
Insulinotherapy 1,037 10.7% 1,217 11.7% 1,390 12.5% 1,512 12.8% 1,615 13.9% 1,299 13.3%
Patients excluded 9,323 10,037 10,418 10,794 12,130 15,128
Lost to follow up 4,562 49% 4,877 49% 4,909 47% 4,821 45% 4,923 41% 4,418 29%
No pharmacological treatment 839 9% 1,152 11% 1,466 14% 1,719 16% 2,008 17% 1,610 11%
Pharmacological treatment with:
Discontinuation period 1,692 18% 1,846 18% 1,907 18% 1,959 18% 2,535 21% 6,411 42%
Non stationary period 1,255 13% 1,070 11% 1,086 10% 1,225 11% 1,432 12% 1,978 13%
Stage changes 975 10% 1,092 11% 1,050 10% 1,070 10% 1,232 10% 711 5%
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Table 2 Definition of diabetic patients with declining renal function
Diabetic patients 25,458
2 Measurements of creatinine clearance and 2 Measurements of urinary protein within a one-year time frame 2,109 8,3%
OR At least one record associated with a long term condition “chronic nephropathy and primitive nephrotic syndrom” and at least
one ICD 10 code related to chronic kidney failure
127 0,5%
OR At least one prescription dispensing of treatment from the following list associated to a nephrologist visit: ACE-I (Angiotensin
converting enzyme inhibitors) and A2RA (Angiotensin II receptor antagonists) in association, phosphorus chelators (*),
polystyrene sulfonate (**), Angiotensin converting enzyme (ACE) inhibitors,
496 1,9%
OR At least two dispensings with an interval from 30 to 365 days of a conbination of following treatment: ACE-I, A2RA,
phosphorus chelators (*), polystyrene sulfonate (**)
170 0,7%
Total number of patients with a chronic kidney failure (CKF) (Declining Renal Function) 2,535 10,0%
Patients with terminal CKF: patients with a CKF and…:
At least 2 records associated with a CCAM code related to dialyse within a One-week time period 67 0,3%
OR At least 2 prescription dispensings of erythropoietin AND 2 prescriptions dispensing of phosphorus chelators within a 45 days-
time period
22 0,1%
Total number of patients with a terminal CKF 80 0,3%
Patients with severe CKF: patients with a CKF… 585 2,3%
At least 2 prescription dispensings of erythropoietin 470 1,8%
OR At least 2 prescription dispensings of phosphorus chelators 140 0,5%
OR At least 4 nephrologist visits within 12-months time frame 58 0,2%
Total number of patients with a severe CKF 585 2,3%
Patients with moderate CKF: Patients with a CKF not defined as severe or terminal
Total number of patients with moderate CKF 1,870 7,3%
Table 3 Socio-demographic and clinical characteristics by treatment stage and renal function status among patients
treated for T2DM in 2010
Patients with normal renal function Patients with declining renal function
Mono-
therapy
Double
therapy
Triple
therapy
Insulin
therapy
Non diabetic
patients
Mono-
therapy
Double
therapy
Triple
therapy
Insulin
therapy
Number of patients 4,353 2,503 728 1,032 27,389 411 267 78 267
Female (N,%) 48.0% 46.1% 43.4% 53.7% 47.6% 45.3% 44.9% 35.9% 47.2%
Age (mean, sd) (1) 67.7 (11.5) 66.3 (11.1) 64.0 (10.1) 67.4 (11.9) 66.9(11.4) 69.6 (11.0) 67.3 (11.6) 66.0 (10.3) 71.4 (10.0)
Out of metropolitan France 4.5% 5.3% 5.9% 8.6% - 6.6% 9.4% 7.7% 10.1%
CMU* beneficiary 2.5% 3.4% 4.3% 3.3% 3.3% 4.9% 6.0% 3.9% 3.0%
Reimbursement rate for antidiabetics
(mean, sd)
90.9 (15.6) 95.7 (12.0) 97.2 (10.3) 98.1 (8.1) - - - - -
Antihypertensive 79.0% 79.0% 81.2% 86,0% 47.8% 88.3% 85.8% 93.6% 96.3%
Antithrombotic agents 41.3% 41.9% 40.3% 60.3% 22.7% 49.4% 44.9% 32.1% 74.5%
Hypolipidemic drugs 62.8% 65.0% 72.1% 69.0% 33.0% 67.4% 67.8% 71.8% 79.8%
ALD*-5: Cardiac Insufficiency 2.8% 1.8% 1.7% 2.4% 1.7% 4.4% 2.3% 2.6% 1.9%
ALD-8: Diabetes 32.9% 50.1% 62.9% 75.6% - 41.6% 56.6% 73.1% 77.9%
ALD-12: Hypertension 10.9% 9.8% 9.9% 10.2% 3.0% 13.1% 18.0% 14.1% 12.0%
ALD-13: Myocardial infarction 5.7% 5.1% 3.7% 5.6% 3.7% 7.5% 3.8% 1.3% 7.1%
ALD-23: Psychosis 4.0% 4.0% 5.5% 6.5% 3.5% 2.9% 3.8% 2.6% 4.5%
ALD-30: Malignant cancer 5.8% 5.0% 3.2% 3.5% 5.5% 7.1% 6.7% 2.6% 5.6%
*CMU = Couverture maladie universelle (Universal health care coverage).
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following criteria: (1) at least 2 measurements of creatinine
clearance and 2 measurements of urinary protein in one
year; (2) at least one long-term condition record with an
ICD-10 code related to chronic renal failure; (3) At least
one nephrologist consultation associated with a prescrip-
tion of treatment from the following list: combination of
angiotensin converting enzyme inhibitors (ACE-I) and
angiotensin II receptor antagonists (A2RA); phosphorus
chelators (calcium carbonate, sevelamer, lanthanum, alu-
minium salts); polystyrene sulfonate); (4) At least two dis-
pensings with an interval from 30 to 365 days of a
combination of following treatment: ACE-I, A2RA, phos-
phorus chelators. This definition was deliberately restrict-
ive in order to minimize the number of false positives.
Based on expert opinion, a patient was considered in a
stable treatment stage if he was in that stage for at least
6 months. As pharmacy claims generally occurred at 1-
month intervals, patients were classified into oral/GLP1
monotherapy (MT), double therapy (DT), triple therapy
(TT) or insulin therapy (IT) (either associated or not
with other antidiabetics) if they had at least 6 consecutive
pharmacy claims for either one, two, three OAD/GLP-1
analog or insulin (± OAD/GLP-1 analog) treatment with-
out discontinuation. The definition of antidiabetic treat-
ment discontinuation was a gap between two claims of
antidiabetic drugs exceeding 6 months. The start date of a
treatment phase was the date of the first of the six con-
secutive claims. The end date of a treatment phase was
defined as the date of the first occurring event among the
following: (1) a new treatment stage starts; (2) first of 5
consecutive dispensings that do not correspond to the
treatment phase; (3) discontinuation.
For each patient, only the years during which the pa-
tient was constantly in the same treatment phase were
considered. Each year, patients were excluded if they
were lost to follow-up (no healthcare resource use dur-
ing 3 months during the calendar year) or discontinued
T2DM treatment.
The estimation of T2DM-attributable expenditures
was based on the difference in expenditures between pa-
tients with T2DM and matched controls without dia-
betes. Controls were randomly selected among insured
persons included into EGB database not selected above
and matched with patients with T2DM according to age
and gender. Each year, controls were excluded from the
analysis if they had no reimbursement claim during the
year or at least one long-term condition record with an
ICD 10 code related to chronic kidney failure before or
during the year of interest.
Estimation of yearly reimbursed expenditures
Total amounts charged by providers and amounts reim-
bursed by the national health insurance are included in all
medical claim records. Therefore healthcare expenditures
from the health insurance perspective were calculated by
summing amounts reimbursed by national health insur-
ance for all healthcare resources consumed by calendar
year, overall and by type of resource. All ambulatory care
resources were included: pharmacy, physician visits and
consultations, nursing care, diagnostic tests, imaging pro-
cedures, physiotherapy, medical devices, transportation…
Two types of expenditures were reported: total expendi-
tures (sum of all reimbursed amounts, related to diabetes
or not) and expenditures attributable to T2DM, estimated
as the mean differences in reimbursed expenditures be-
tween patients with T2DM and matched controls without
T2DM.
Statistical analysis
In order to estimate expenditures attributable to dia-
betes, each case was matched to 2 controls without dia-
betes with same year of birth and same gender, using a
greedy matching algorithm. In addition, to estimate the
effect of treatment phase, patients with T2DM in a given
treatment phase were matched to patients with T2DM
at earlier treatment phase in same calendar year, with
Figure 2 Total ambulatory care individual expenditures (€) according to time and treatment stage.
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Table 4 Total ambulatory care expenditures according to time and treatment phase for patients (€)
2005 2006 2007 2008 2009 2010
N Mean SD N Mean SD N Mean SD N Mean SD N Mean SD N Mean SD
Patients with Normal Renal Function
Monotherapy 5,507 2,703 3,333 5,543 2,711 3,407 5,682 2,821 3,542 5,921 2,971 3,916 5,538 2,980 3,876 4,353 3,017 3,829
Double therapy 2,324 2,884 3,113 2,587 2,935 3,206 2,762 3,095 3,622 2,839 3,125 3,611 2,786 3,171 3,861 2,503 3,308 4,045
Triple therapy 328 3,473 3,121 406 3,295 3,013 505 3,313 2,938 587 3,180 3,011 658 3,264 3,312 728 3,609 3,801
Insulin therapy 898 6,759 5,203 1,029 6,800 5,192 1,150 7,063 5,573 1,214 7,058 5,903 1,256 7,228 5,658 1,032 7,398 5,487
Non diabetic patients 27,389 1,715 2,914 28,962 1,767 3,060 30,618 1,866 3,261 32,103 1,994 3,475 31,128 2,150 3,979 26,253 2,166 4,102
Patients with Declining Renal Function
Monotherapy 282 4,148 4,258 339 4,267 4,426 393 4,396 4,811 465 4,897 6,427 518 4,149 4,637 411 4,226 5,369
Double therapy 157 3,773 3,144 228 3,603 3,628 266 3,667 3,257 308 3,892 4,004 310 3,891 4,623 267 4,159 5,268
Triple therapy 27 4,244 3,641 41 3,105 1,617 45 4,052 3,396 69 4,203 4,411 71 3,387 3,027 78 4,032 4,329
Insulin therapy 136 10,772 9,335 188 10,227 8,882 240 10,644 10,731 294 10,499 10,185 359 11,155 11,188 267 11,344 11,185
G
u
e
lfu
cci
et
a
l.
B
M
C
E
n
d
o
crin
e
D
iso
rd
ers
2
0
1
3
,
1
3
:1
5
P
a
g
e
6
o
f
1
2
h
ttp
://w
w
w
.b
io
m
e
d
ce
n
tra
l.co
m
/1
4
7
2
-6
8
2
3
/1
3
/1
5
Table 5 Details of individual ambulatory care expenditures for patients with T2DM and normal renal function and for non-diabetic controls in 2010 (€)
Consultations
visits
Physio-
therapist
Nursing
care
Biological
diagnostic tests
Radiology/medical
imaging
Medical
devices
Transportation Invalidity Pharmacy Others Total ambulatory
care costs
Monotherapy (mono):
m (σ)
256 (190) 90 (339) 144 (853) 159 (175) 113 (191) 272 (861) 88 (449) 219
(1,451)
1,156
(1,786)
521 (1,528) 3,017 (3,829)
Double therapy (bi):
m (σ)
257 (156) 88 (372) 152(885) 155 (158) 107 (186) 294 (728) 98 (787) 240
(1,730)
1,411
(1,650)
506 (1,679) 3,308 (4,045)
Cost ratio vs mono 1.045 0.909 1.392 1.070 0.940 1.237 1.113 0.976 1.236 0.885 1.102
Triple therapy (tri):
m (σ)
252 (146) 55(280) 94 (646) 149 (129) 110 (188) 272 (410) 112 (707) 308
(1,857)
1,798
(1,509)
460 (1,337) 3,609(3,801)
Cost ratio vs bi 1.044 0.728 0.675 0.977 1.038 1.059 1.022 1.026 1.287 0.926 1.101
Insulin therapy: m (σ) 329 (208) 157 (499) 1,586 (2761) 198 (210) 140 (221) 1,216
(1,697)
264 (1,064) 444
(2,025)
2,646
(2,124)
420 (1,093) 7,398(5,487)
Cost ratio vs tri 1.200 2.509 18.420 1.189 1.178 3.931 2.480 2.929 1.331 1.228 1.942
Non diabetic patients 175 (184) 81 (324) 101 (977) 93 (176) 95 (170) 160 (805) 85 (582) 136
(1,131)
702 (2,142) 538 (1,799) 2,166 (4,102)
Additional costs vs non diabetic patients: € (increase rate in %)
Monotherapy 80 (46.3%) 9 (11.1%) 43 (42.6%) 66 (71.0%) 18 (18.9%) 112 (70.0%) 3 (3.5%) 83 (61.0%) 454 (64.7%) −17 (-3.2%) 852 (39.3%)
Double therapy 81 (46.9%) 7 (8.6%) 51 (50.5%) 62 (66.7%) 12 (12.6%) 134 (83.8%) 13 (15.3%) 104
(76.5%)
709
(101.0%)
−32 (-5.9%) 1,142 (52.7%)
Triple therapy 77 (44.0%) −26
(-32.1%)
−7 (-6.9%) 56 (60.2%) 15 (15.8%) 112 (70.0%) 27 (31.8%) 172
(126.5%)
1,096
(156.1%)
−78
(-14.5%)
1,444 (66.7%)
Insulin therapy 154 (88.0%) 76 (93.8%) 1,485
(1,470.3%)
105 (112.9%) 45 (47.4%) 1,056
(660.0%)
179 (210.6%) 308
(226.5%)
1,944
(276.9%)
−118
(-21.9%)
5,234 (241.7%)
*Cost ratios from Generalized Linear Models (GLM), adjusted on year, socio demographic patient characteristics, long-term conditions, co-treatments.
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same year of birth and gender. The matching ratio was
1:2 for DT vs MT; 1:3 for IT vs DT; and 1:2 for IT vs
MT. The matching algorithms were applied for each
year successively.
Effects of treatment stages on annual ambulatory care
expenditures were analysed by means of generalised lin-
ear models with a log link function and negative bino-
mial distribution, adjusting on patient characteristics not
included in matching variables (area of residence, eligi-
bility for full reimbursement of healthcare for people
who cannot afford a private top-up health insurance),
calendar year, and clinical characteristics such as co-
prescriptions (cardiovascular and antihypertensive drugs)
and long terms conditions. All analyses were performed
using SAS software version 9.1.
Results
A total of 25,458 patients treated for T2DM were se-
lected. The proportion of patients treated was stable
over time (Figure 1; Table 1). 2,535 (10%) patients had
DRF (Table 2). The number of patients continuously
treated in one phase over a calendar year ranged from
9,682 to 11,772 between 2005 and 2010. The proportion
of patients in IT among patients continuously treated in
one phase, increased from 10.7% in 2005 to 13.9% in
2009 (Table 1). Each year, around half of the patients
were excluded from the transversal analysis due to the
high proportions of patients lost to follow-up or discon-
tinuing their treatment.
The average age was between 64 and 68 years old in
2010 among patients with normal renal function (NRF),
according to treatment phase, increasing by 1 to 2 years
compared to 2005. The prevalence of specific cardiovas-
cular drug co-prescriptions was higher in patients with
T2DM than in the control group, and was the highest
for those treated by insulin. All patients with diabetes
are entitled to full reimbursement health care expenses
related to diabetes and associated long-term conditions,
therefore average reimbursement rates of antidiabetics
are high, from 90% to 98% (Table 3). There was no
major difference in demographic characteristics between
patients with or without DRF.
Ambulatory care expenditures over time
Individual annual ambulatory care expenditures increased
from €2,703 in 2005 to €3,017 in 2010 for patients in MT
(+11.6%), from €2,884 to €3,308 in DT (+14.7%) and from
€6,759 to €7,398 in IT (+9.4%) (Figure 2; Table 4). These
increase rates are lower than the rate for controls without
diabetes (+26.3%). Quasi-stability is observed for patients
in TT (+0.2% from €3,473 to €3,482) (Figure 2).
Individual ambulatory care expenditures in 2010
In 2010, annual individual ambulatory care expenditures
slightly increased from MT (€3,017 [95%CI: €3,015;
€3,019]) to DT (€3,308 [€3,305;€3,311]), and from DT to
TT (€3,609 [€3,599;€3,619]). Switching from OADs/
GLP-1 analogs to insulin led to an increase in individual
ambulatory care expenditures to €7,398 [€7,388;€7,408].
This substantial increase was also found in other years
and is mainly attributable to nursing care (+1,000% vs.
MT), medical devices (+347%), transportation (+200%)
and pharmacy expenditures (+129%) (Table 5).
The regression model showed that individual ambulatory
expenditures increased by a ratio of 1.94 (p < 0.001) from
TT to IT, with adjustment for socio-demographic charac-
teristics and co-treatments. Nursing care costs increased by
a ratio of 18.42 (p < 0.001), medical devices costs (including
glucose monitoring device) by 3.93 (p < 0.001) and phar-
macy costs by 1.33 (p < 0.001) (Table 5).
The drug costs increased with treatment escalation:
from €1,113 (€3.04/day) in MT to €1,381 in DT (€3.78/
day), to €1,701 (€4.66/day) in TT and to €2,615 (€7.16/
day) in IT. Pharmacy is the first cost category account-
ing for 38% of ambulatory care expenditures in MT, 43%
in DT, 50% in TT and 36% in IT (Tables 6 and 7).
Average costs of antidiabetic drugs in 2010 (insulin/
OADs/GLP-1 analogs) were €136 (€0.37/day) in MT,
€390 (€1.07/day) in DT, €753 (€2.06/day) in TT and
Table 6 Impact of the treatment phase on the annual ambulatory healthcare expenditures attributable to diabetes for
patients with T2DM with normal renal function (€) (Adjusted model on differences in expenditures between T2-DM
patients and matched individuals without diabetes)
Treatment phases (ref = monotherapy) Pharmacy Consultations Medical devices Nursing cares Others Total ambulatory costs
Double therapy 238*** 9*** 26*** 9 −31 224***
(213;262) (6;12) (15;38) (-5;23) (-71;9) (169;280)
Triple therapy 556*** 16*** 35** −30* −131*** 411***
(509;603) (11;21) (13;57) (-56;-4) (-208;-55) (306;517)
Insulin therapy 1,224*** 78*** 863*** 1,236*** 1,268*** 3,807***
(1,190;1,259) (74;82) (847;880) (1,217;1,256) (1,212;1,325) (3,730;3,885)
* 0.01 < p < 0.05; ** 0.001 < p < 0.01; *** p < 0.001.
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€1,060 (€179 for OADs and €881 for insulin, €2.90/day)
for patients with insulin (Table 7). The cost of insulin
alone does not explain the substantial cost increase
when moving to this final treatment phase (Figure 3;
Table 6).
DM-attributable expenditures mainly consist of drug
costs for patients without insulin (€1,096 for TT). In
addition, significantly higher DM-attributable costs re-
lated to nursing care (€1,485) and medical devices
(€1,056) are incurred for patients with insulin (Figure 4).
DM-attributable drug costs are largely related to
antidiabetic drugs (from 28% in MT to 71% in TT; 54%
in IT), and also to cardiovascular system drugs (21% in
IT to 51% in MT) and nervous system drugs (from 3%
in TT in to 8% in IT) as shown in Figure 3.
The regression analysis shows an increase of €224/pa-
tient in the ambulatory expenditures attributable to
T2DM between MT and DT, i.e + 26% (see Table 7). This
Table 7 Details of medication costs by drug class and treatment phase (€)
Mono therapy Double
therapy
Triple
therapy
Insulin
therapy
Non
diabetics
Mean SD Mean SD Mean SD Mean SD Mean SD
A-Alimentary tract and metabolism
Insulin €4 (€37) €10 (€55) €12 (€63) €881 (€516) €3 (€54)
Oral antidiabetic agents €129 (€114) €367 (€201) €647 (€244) €147 (€196) - -
GLP-1 Analog €3 (€50) €13 (€121) €94 (€319) €32 (€185) - -
Other alimentary tract and metabolism products €75 (€136) €64 (€111) €64 (€116) €121 (€174) €55 (€125)
B-Blood and blood forming organs
Antithrombotic agents €61 (€154) €69 (€172) €61 (€170) €127 (€291) €34 (€120)
Antihemorrhagics €0 (€1) €1 (€68) €0 (€0) €0 (€3) €0 (€55)
Antianemic preparations €18 (€396) €18 (€287) €7 (€106) €46 (€670) €12 (€296)
Blood substitutes and perfusion solutions €1 (€15) €0 (€2) €0 (€3) €1 (€7) €2 (€70)
C- Cardiovascular system
Cardiac therapy €24 (€87) €20 (€72) €15 (€52) €43 (€120) €14 (€57)
Antihypertensive €10 (€49) €13 (€55) €15 (€61) €19 (€65) €4 (€27)
Diuretics €14 (€52) €12 (€37) €11 (€66) €24 (€77) €6 (€34)
Beta-blocking agents €33 (€62) €33 (€60) €33 (€58) €43 (€76) €15 (€40)
Calcium channel blockers €31 (€65) €33 (€66) €32 (€67) €40 (€72) €14 (€43)
Agents acting of the renin-angiotensin system €152 (€147) €171 (€155) €196 (€160) €207 (€163) €61 (€105)
Lipid modifying agents – Statins €127 (€162) €146 (€179) €177 (€185) €190 (€201) €52 (€113)
Lipid modifying agents - Other €19 (€76) €19 (€81) €20 (€89) €24 (€109) €10 (€53)
Other cardiovascular system drugs €4 (€23) €4 (€24) €5 (€30) €8 (€36) €2 (€17)
D-Dermatologicals €10 (€40) €11 (€43) €13 (€61) €18 (€61) €7 (€32)
G-Genito urinary system and sex hormone €15 (€65) €13 (€58) €12 (€51) €18 (€72) €14 (€52)
H-Systemic hormonal preparations, excl. sex hormones and
insulins
- - - - - - - - €8 (€192)
J-Antiinfectives for systemic use €39 (€419) €36 (€418) €19 (€39) €69 (€416) €38 (€492)
L-Antineoplastic and immunomodulating agents €70 (€881) €82 (€921) €27 (€233) €141 (€1371) €78 (€906)
M-Musculo-skeletal system €27 (€88) €25 (€63) €27 (€121) €24 (€56) €28 (€98)
N-Nervous system €0 (€0) €0 (€0) €0 (€0) €0 (€0) €0 (€0)
Psychotropics €50 (€241) €42 (€183) €44 (€145) €82 (€246) €33 (€146)
Other nervous system product €91 (€255) €92 (€269) €92 (€247) €181 (€430) €74 (€293)
P-Antiparasitic products, insecticides and repellents €0 (€5) €0 (€3) €1 (€6) €1 (€7) €0 (€0)
R-Respiratory system €58 (€223) €46 (€173) €46 (€179) €86 (€295) €43 (€188)
S-Sensory organs €38 (€279) €32 (€230) €24 (€118) €33 (€193) €29 (€275)
V-Various €9 (€139) €8 (€72) €5 (€17) €8 (€28) €9 (€255)
Total €1113 (€1,411) €1,381 (€1,435) €1,701 (€868) €2,615 (€2,089) €644 (—)
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difference reached €411 between MT and TT (+48%)
but the largest increase was observed during the transi-
tion to insulin, equal to €3807 (+447%) and €3396
(+269%) compared to MT and TT respectively. This ana-
lysis also showed substantial increase rates associated
with the transition to insulin, for other resource categor-
ies, especially nursing care.
Patients with declining renal function
Individual ambulatory care expenditures for patients
with DRF exceeded those for patients with NRF by 12%
(TT) to 53% (IT), with estimated totals of €4,226
[€4,200;€4,252] for MT in 2010, €4,159 [€4,120;€4,198]
for DT, €4,032 [€3,923;€4,141] for TT and €11,344
[€11,262;€11,426] for IT (Table 8). The same cost pat-
tern was found for previous years.
Discussion
The results of this study show that individual ambula-
tory care expenditures for patients with T2DM increased
moderately and progressively from 2005 to 2010. In-
crease rates were lower for patients with T2DM in a
stable treatment stage (< 15%), than for controls without
diabetes (26%) with an average annual rate (from 0.9%
for TT to 2.8% for DT) close to the inflation rate (from
1.5% to 2.8%) over the same period (except 2009). The
introduction of new classes of antidiabetic drugs in
2008-2009 (DPP4 and GLP-1 analogs) did not appear to
have any substantial impact on overall health care ex-
penditures for DM patients over the considered period.
In addition, individual yearly ambulatory care expen-
ditures increased with treatment escalation. Insulin
therapy was associated with substantial cost increase
compared to earlier stages of treatment, related to
Figure 3 Additional individual direct drug costs attributable to T2DM by treatment phase and resource category in 2010. *% calculated
by treatment line; ex: additionnal drug costs in monotherapy = 28% antidiabetics, 51% cardiovascular system, 7% nervous system 7% blood and blood
forming organs, 7% others.
Figure 4 Additional individual ambulatory care expenditures attributable to T2 DM by treatment phase and resource category in
2010*. *% calculated by treatment line; ex: additional costs in monotherapy = 53% pharmacy + 9% consultations + 5% nursing care + 32% others.
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pharmacy but also nursing care and medical devices util-
isation. Additional drug costs attributable to diabetes are
not only related to antidiabetic drugs and insulin but
also to other drugs, mainly cardiovascular system and
psychotropic drugs (antidepressants and analgesics). Al-
though adjustments for patient socio-demographics and
co-treatments were used, it cannot be ruled out that a
residual part of the estimated difference in expenditures
between insulin-treated patients and other DM patients
is attributable to worsening health status. However, a
large part of those additional expenditures appears to be
directly related to administration of insulin, as suggested
by high rates of increase in costs of nursing care and
medical devices.
In addition, individual yearly expenditures for DM pa-
tients with DRF were showed to exceed expenditures for
other DM patients by +12% (TT) to +53% (IT), again
with substantial nursing care and medical device costs
for patients treated with insulin.
The estimated expenditures reported here are consist-
ent with results of previous studies on the costs of dia-
betes in France. Ambulatory care expenditures were
approximately €3,400 in 2007, among patients with or
without insulin, compared to €3,300 (excluding hospital-
isation) in ENTRED. The pharmacy expenditures esti-
mates (€1,156, €1,411 and €1,798 in MT, DT and TT)
are also comparable to those from the ENTRED study
(around €1,400) [4]. A review on costs of diabetes in
France suggested that costs in patients with insulin are
about twice as much as in patients treated with oral an-
tidiabetics, which is also consistent with our findings [7].
However, the cost difference between patients with and
without insulin was thought to be largely attributable to
complications [8]. In addition, the importance of nursing
care costs in patients with insulin is corroborated by a
recent French publication focusing on the costs associ-
ated with insulin therapy [9]: nursing care (€25.8/week)
was the most important contributor to the costs of
insulin-therapy (€45.4/week).
Real-world healthcare expenditures were measured in
this study by analyzing health insurance claims data.
The strengths of the EGB database, relative to other
health insurance databases in Western countries, include
its size, its representativity, the absence of selection
according to clinical or socioeconomic criteria, and the
fact that most persons are continuously enrolled. How-
ever, this study has limitations related to the utilisation
of administrative data, rather than clinical data. Thus,
the identification of patients with DRF was based on
very restrictive assumptions. We estimated the propor-
tion of patients with DRF at 10%, whereas higher esti-
mates have been reported [10,11]. This implies that the
groups of patients with NRF probably included a few
patients with DRF.
The EGB database contains no other socio-demographic
data than age, sex, date of death, residence department
and the affiliation in the CMU. Education level, income
level or occupational category of beneficiaries, for which
the influence on health care consumption has been dem-
onstrated [12,13], are absent from the EGB. This informa-
tion should be collected through specific surveys.
The description of the results over time does not con-
sider all treated DM patients but only focuses on the
subpopulation of DM patients that are stable in their
treatment. Patients not stable or switching from a treat-
ment to another within the year were excluded from the
analysis. This facilitated the comparison of expendi-
tures between treatment stages but also introduced a
selection bias that might affect the description of
expenditures for the overall population. In particular,
expenditures of switching between different treatment
stages were not captured. The reported estimations are
therefore conservative, reflecting the most stable and
compliant patients.
Table 8 Individual ambulatory care expenditures for patients with type T2DM and declining renal function in 2010 (€)
Pharmacy Consultation (GP/specialist) Nursing care Total ambulatory care costs
Monotherapy (N = 411) m (σ) 1,798 (2,433) 307 (252) 143 (683) 4,226 (5,369)
Increase rate vs NRF 56% 20% 0% 40%
Double therapy (N = 267) m (σ) 1,893 (3,908) 301 (171) 210 (963) 4,159 (5,268)
Cost ratio vs mono (%) 1.094* 0.978 0.736 0.959
Increase rate vs NRF 34% 21% 38% 26%
Triple therapy (N = 78) m (σ) 2,141 (3,056) 305 (152) 99 (504) 4,032 (4,329)
Cost ratio vs mono (%) 1.262 *** 1.029 0.903 1.031
Increase rate vs NRF 19% 17% 5% 12%
Insulin therapy (N = 267) m (σ) 3,889 (5,363) 422 (340) 2,161 (3,638) 11,344 (11,185)
Cost ratio vs mono (%) 2.020 *** 1.230 *** 10.236 *** 2.223***
Increase rate vs NRF 47% 28% 36% 53%
* 0.01 < p < 0.05; ** 0.001 < p < 0.01; *** p < 0.001.
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Some patients in a stable treatment phase were not
identified in 2010, as suggested by patient numbers by
year. The selection method was based on restrictive cri-
teria and the absence of data after December 2010 led to
exclude several patients, classified as lost to follow-up.
Conclusions
In conclusion, individual ambulatory care expenditures
are substantially higher among patients with T2DM in a
stable treatment phase, but have grown at a slower rate
than in controls without diabetes with same age and
gender over recent years up to 2010. Pharmacy is the
first category of ambulatory care expenditures associated
with diabetes; this is not only due to costs of antidiabetic
drugs, but also to treatment of comorbidities. This study
also highlighted two key determinants of ambulatory
care expenditures among patients with T2DM: treatment
stage and renal function status. Individual ambulatory
care expenditures increase with treatment escalation,
and most particularly transition to insulin therapy, be-
cause of pharmacy costs, nursing care and medical de-
vices utilisation. Expenditures for patients with DRF are
higher than for patients without DRF, at all treatment
stages, and particularly for insulin users. These findings
provide an economic argument for maintaining the dia-
betic patients under oral treatments as long as they can
be controlled by oral treatment. Finally, this study sug-
gests that the introduction of new oral antidiabetic treat-
ments had little impact on the total ambulatory care
expenditure for patients with T2DM.
Abbreviation
ACE-I: Angiotensin converting enzyme inhibitors; ALD: Affections longues
durées (long term conditions); A2RA: Angiotensin II receptor antagonists;
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CRD: Chronic renal disease; DPP4: Dipeptidyl peptidase-4 inhibitors;
DRF: Declining renal function; DT: Double therapy; EGB: Echantillon
generaliste de beneficiaires (general sample of beneficiaries);
ENTRED: Echantillon national témoin représentatif des personnes
diabétiques; GLP-1: Glucagon-like peptide-1; HAS: haute autorité de Santé
(the French national authority for health); IT: Insulin therapy; OADs: Oral
antiDiabetics; MT: Monotherapy; T2DM: Type 2 diabetes mellitus; TT: Triple
therapy.
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